Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Express Scripts $29.1 billion bid for Medco will hit US FTC scrutiny and squeeze pharma

This article was originally published in Scrip

Executive Summary

Express Scripts has agreed to buy rival pharmacy benefits manager Medco Health Solutions in a cash and stock deal that values Medco at about $71.36 a share, or $29.1 billion. The price represents a 28% premium to Medco's closing price of $55.78 immediately before the deal was announced. The move came as a shock to some, but investors who have been watching the pressures facing Medco feel the timing is right.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts